These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1376951)

  • 1. Protection from herpes simplex virus type 2 is associated with T cells involved in delayed type hypersensitivity that recognize glycosylation-related epitopes on glycoprotein D.
    Wachsman M; Luo JH; Aurelian L; Paoletti E
    Vaccine; 1992; 10(7):447-54. PubMed ID: 1376951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease.
    Wachsman M; Aurelian L; Smith CC; Perkus ME; Paoletti E
    J Infect Dis; 1989 Apr; 159(4):625-34. PubMed ID: 2538519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
    Aurelian L; Smith CC; Wachsman M; Paoletti E
    Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of herpes simplex virus glycoprotein D on antigen presenting cells infected with vaccinia recombinants and protective immunity.
    Wachsman M; Aurelian L; Hunter JC; Perkus ME; Paoletti E
    Biosci Rep; 1988 Aug; 8(4):323-34. PubMed ID: 3263886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanisms of antiviral immunity induced by a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: clearance of local infection.
    Martin S; Rouse BT
    J Immunol; 1987 May; 138(10):3431-7. PubMed ID: 3033075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-presenting capacity of epidermal cells infected with vaccinia virus recombinants containing the herpes simplex virus glycoprotein D, and protective immunity.
    Wachsman M; Luo JH; Aurelian L; Perkus ME; Paoletti E
    J Gen Virol; 1989 Sep; 70 ( Pt 9)():2513-20. PubMed ID: 2550579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
    Rooney JF; Wohlenberg C; Cremer KJ; Moss B; Notkins AL
    J Virol; 1988 May; 62(5):1530-4. PubMed ID: 2833606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.
    Chan WL; Lukig ML; Liew FY
    J Exp Med; 1985 Oct; 162(4):1304-18. PubMed ID: 2995536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of antiviral immunity using vaccinia virus recombinants expressing cloned genes for herpes simplex virus type 1 glycoproteins.
    Martin S; Cantin E; Rouse BT
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1359-70. PubMed ID: 2543783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed hypersensitivity and immune protection against herpes simplex virus: suppressor T cells that regulate the induction of delayed hypersensitivity effector T cells also regulate the induction of protective T cells.
    Schrier RD; Ishioka GY; Pizer LI; Moorhead JW
    J Immunol; 1985 May; 134(5):2889-93. PubMed ID: 2580006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.
    Wachsman M; Aurelian L; Smith CC; Lipinskas BR; Perkus ME; Paoletti E
    J Infect Dis; 1987 Jun; 155(6):1188-97. PubMed ID: 3033094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proportion of herpes simplex virus-specific cytotoxic T lymphocytes (Tc) that recognize glycoprotein C varies between individual mice and is dependent on the form of immunization.
    Martin S; Mercadal CM; Weir JP; Rouse BT
    Viral Immunol; 1993; 6(1):21-33. PubMed ID: 8386515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baculovirus-expressed glycoprotein H of herpes simplex virus type 1 (HSV-1) induces neutralizing antibody and delayed type hypersensitivity responses, but does not protect immunized mice against lethal HSV-1 challenge.
    Ghiasi H; Kaiwar R; Nesburn AB; Wechsler SL
    J Gen Virol; 1992 Mar; 73 ( Pt 3)():719-22. PubMed ID: 1312127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live vaccinia virus recombinants expressing herpes simplex virus genes.
    Rooney JF; Wohlenberg CR; Moss B; Notkins AL
    Rev Infect Dis; 1991; 13 Suppl 11():S898-903. PubMed ID: 1664124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
    Karem KL; Bowen J; Kuklin N; Rouse BT
    J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
    Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
    Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection.
    Goel N; Rong Q; Zimmerman D; Rosenthal KS
    Vaccine; 2003 Oct; 21(27-30):4410-20. PubMed ID: 14505924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
    Cremer KJ; Mackett M; Wohlenberg C; Notkins AL; Moss B
    Science; 1985 May; 228(4700):737-40. PubMed ID: 2986288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of T cell responses to glycoprotein B (gB-1) of herpes simplex virus type 1 and its non-glycosylated precursor protein, pgB-1.
    O'Donnell CA; Chan WL
    Clin Exp Immunol; 1991 Oct; 86(1):30-6. PubMed ID: 1655317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.